Coleraine Pty Ltd is a limited by shares, Australian proprietary company. This corporation was registered on 2004-03-18 and was issued with the 108413083 ACN. Its Australian Business Number is 28108413083. Since 2004-07-10, the company is headquartered in NSW, post code 2230. The previous headquarters were located in NSW 2230 (from 2004-07-05 to 2004-07-10). The above data comes from the ABN database which was updated on 2004-07-10. Aubiz
Status | From | To |
---|---|---|
Active | 2004-07-05 | current |
Name | From | To |
---|---|---|
Coleraine Pty Ltd | 2004-07-05 | current |
Location | From | To |
---|---|---|
NSW 2230 | 2004-07-10 | current |
NSW 2230 | 2004-07-05 | 2004-07-10 |
Advertisements
Lodgement date: | 2010-09-06 |
Live or dead: | Live |
CPI status: | Never Registered |
Status: | AFS Indexing Approved |
Mark code: | Trade Mark |
Trademark type: | Word |
Court orders: | No |
Revocation of the acceptance: | No |
Goods and services assistance: | Yes |
Lodgement type: | AFS |
Descriptive: | Infinitypharma |
NICE class code: | 5 |
NICE occ number: | 2 |
NICE description text: | (pharmaceuticals); Regimen Preparations (pharmaceuticals); Skin Patches For The Transdermal Delivery Of Pharmaceuticals; Sprays For Use On The Body (pharmaceuticals); Tablets (pharmaceuticals); Transdermal Patches For Administering Pharmaceuticals |
Suburb name: | Burraneer |
Postcode: | 2230 |
Australian state code: | NSW |
Country code: | AU |
Contains public sector information licensed under the Creative Commons Attribution 3.0 Australia licence. Material on this website was obtained from publicly-accessible databases and is attributed to ©Commonwealth of Australia 2024 (http://data.gov.au, http://acnc.gov.au/ and http://abr.business.gov.au/), ©Intellectual Property Government Open Data 2024, ©ASIC - Company Register. While we try to make the information as precise and up-to-date as possible, we are aware the datasets are not always error-free. Aubiz.net will not take responsibility for any errors in the databases. The material provided should be treated as a starting point of more in-depth research, not as fact.